MBXBF (Microbix Biosystems) LT-Debt-to-Total-Asset: 0.17 (As of Mar. 2026)

What is Microbix Biosystems LT-Debt-to-Total-Asset?

Microbix Biosystems MBXBF -3.14% 55 LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus rates MBXBF with a GF Score™ of 55/100 and a GF Value™ of $0.17 (Modestly Overvalued). The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Microbix Biosystems's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.17.

Microbix Biosystems's long-term debt to total assets ratio increased from Mar. 2025 (0.13) to Mar. 2026 (0.17). It may suggest that Microbix Biosystems is progressively becoming more dependent on debt to grow their business.

Microbix Biosystems (OTCPK:MBXBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Microbix Biosystems LT-Debt-to-Total-Asset Related Terms

Microbix Biosystems LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems LT-Debt-to-Total-Asset Chart

Microbix Biosystems Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.18

0.17

0.18

0.16

0.18

Microbix Biosystems Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.16	0.18	0.18	0.17

55GF Score

Microbix Biosystems Inc MBXBF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Microbix Biosystems LT-Debt-to-Total-Asset Calculation

Microbix Biosystems's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )	/	Total Assets (A: Sep. 2025 )
	=	4.74	/	27.042
	=	0.18

Microbix Biosystems's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	4.267	/	25.776
	=	0.17

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.17 mean?

Microbix Biosystems (MBXBF) has a LT-Debt-to-Total-Asset of 0.17 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Microbix Biosystems and its competitors.

Is Microbix Biosystems' LT-Debt-to-Total-Asset too high?

Microbix Biosystems' current LT-Debt-to-Total-Asset is 0.17. Overall, Microbix Biosystems has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Microbix Biosystems' LT-Debt-to-Total-Asset compare to VRTX and REGN?

Microbix Biosystems' LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Microbix Biosystems stock overvalued right now?

Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.17, compared to a current price of $0.20 — trading 19.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.17. Microbix Biosystems' overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (MBXBF) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of $0.20 is trading 19.6% above its estimated GF Value™ of $0.17. GuruFocus considers Microbix Biosystems to be Modestly Overvalued.

Key valuation signals for MBXBF:

LT-Debt-to-Total-Asset: 0.17
GF Value™: $0.17 vs. price of $0.20 (19.6% above fair value)
GF Score™: 55/100 with 8 warning signs

No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microbix Biosystems Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:DTC TSX:BCT NEOE:ONCO XCNQ:QNTM TSX:MDNA TSXV:ALZI TSXV:MIR TSXV:SHRX TSXV:NRX TSX:RVX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges MBX:Canada

Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3

Website https://www.microbix.com

Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.

55GF Score

Get the complete analysis for MBXBF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20

Price

$0.17

GF Value

View MBXBF Analysis

See LT-Debt-to-Total-Asset data for all stocks →